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Abstract  
Background  
We aimed to evaluate the dynamics of treatment response with different composite measures 
in the Tight Control of Inflammation in early Psoriatic Arthritis (TICOPA) trial.  
Methods 
Participants with early, DMARD naïve psoriatic arthritis (PsA) were randomised 1:1 to either 
tight control (TC, 4 weekly review with therapy escalation if criteria not met) or standard care 
(SC, 12 weekly review).  We calculated modified versions of the Psoriatic ArthritiS Disease 
Activity Score (PASDAS), GRAPPA Composite scorE (GRACE) and Composite Psoriatic 
Disease Activity Index (CPDAI) at baseline and 12 weekly to 48 weeks by blinded assessor. 
For missing data we used the last observation carried forward. Comparison between groups 
was made by analysis of covariance and comparison of area under the curve (AUC). 
Results 
206 people were randomised to TC (n=101) or SC (n=105). Significant differences between 
treatment groups were seen (p < 0.0001 for all composite measures). AUC analysis 
demonstrated a significant difference between groups for the PASDAS but not GRACE and 
CPDAI. For participants with oligoarthritis a significant difference between groups was seen 
for each measure, although the significance levels were greatly diminished (PASDAS, p = 
0.04; GRACE p = 0.01; CPDAI p = 0.04). For oligoarthritis using AUC analysis, none of the 
measures could distinguish between groups.  
Conclusions  
Composite measures of disease activity were able to distinguish between TICOPA treatment 
arms , although differences were diminished for those with oligoarthritis. Further data are 
needed to inform the preferred composite measure for use as the primary outcome in PsA 
trials. 
 
Key words: psoriatic arthritis, treatment, composite measures, disease activity, outcome 
assessment 
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Introduction 
Psoriatic arthritis (PsA) is a heterogeneous disease which can manifest in several ways 
including arthritis, enthesitis, dactylitis, axial disease and skin/nail involvement. The lack of a 
specific validated target for PsA means that the primary outcome measure used in recent 
interventional studies has been the American College of Rheumatology 20% improvement 
(ACR20) criteria, a measure originally developed for rheumatoid arthritis focusing on 
peripheral joint activity (1). However, new composite targets encompassing the complex 
manifestations of PsA have been developed. These include the Psoriatic Arthritis Disease 
Activity Score (PASDAS) and the GRAPPA CompositE Index (GRACE) (2), and, in addition, 
the Composite Psoriatic Disease Activity Index (CPDAI) (3). In addition to measuring 
disease activity at any point in time, these indices can also serve as responder indices and 
cut-offs for response have been developed (4). 
The TIght COntrol in Psoriatic arthritis (TICOPA) study was the first study to demonstrate that 
tight control of disease utilising pre-defined activity levels to guide therapeutic changes 
resulted in significantly better clinical outcomes compared to standard care (5).  In the TICOPA 
study the odds of achieving an ACR20 response at 48 weeks was twofold higher in the treat 
to target arm. However, the outcomes at intervening time points for each arm of the study 
were not described, nor were validated composite disease activity measures for PsA reported. 
In this study we evaluated treatment responses in the TICOPA study using the PASDAS, 
GRACE and CPDAI indices and compared their performance. 
 
Methods 
The primary results of the TICOPA study have already been published (5). In brief this 
randomised, controlled, parallel group, open label, multi-centre clinical trial recruited people 
with early (less than 2 years), treatment naive PsA.  The full trial protocol is also available 
(6).The primary objective of the trial was to compare tight control (TC) with standard care (SC), 
using minimal disease activity (MDA(7)) as the treatment target. Participants received either 
TC or SC for a period of 48 weeks. Participants randomised to TC were seen every 4 weeks 
by the study physician and treated according to a predefined treatment protocol.  Participants 
randomised to the SC arm were treated in a general rheumatology outpatient clinic supervised 
by a consultant rheumatologist.  These patients were generally reviewed every 12 weeks but 
were seen more often if clinically indicated, with no formal measures of disease activity used 
in clinical decision making. A blinded assessor collected clinical assessments and patient 
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reported outcomes every 12 weeks, and the composite disease activity measures were 
derived from these. 
Composite measures: 
Derived Psoriatic Arthritis Disease Activity Score (PASDAS) 
The PASDAS is a weighted index comprising assessments of joints, function, acute phase 
response and quality of life and patient and physician visual analogue scores (VAS). It is 
given by the formula: 
3$6'$6 [¥3K\VLFLDQJOREDO9$6[¥3DWLHQWJOREDO9$6- (0.253 x 
¥6)- PCS) + (0.101 x LN (Swollen joint count + 1)) + (0.048 x LN (Tender joint count + 
1)) + (0.23 x LN (Leeds Enthesitis Count + 1)) + (0.377 LN (Dactylitis count + 1)) + (0.102 x 
LN (CRP + 1)) +2)*1.5. 
Where LN = natural logarithm, PCS = physical component summary scale of SF36, CRP = C 
reactive protein in mg/L. All VAS scores are 0 ± 100 mm. Swollen joint count is 66 joints, and 
tender joint count 68. In this study the SF36 was not completed so an estimate of this 
outcome was calculated using the following formula: 
sf36pcs = 51.615 - (6.52 * HAQ) - (1.529 * BASDAI) - (0.429 * PsAQoL) 
where: sf36pcs is the estimated physical component score of the SF36, HAQ is the Heath 
Assessment Score (range 0 ± 3)(8), BASDAI is the Bath Ankylosing spondylitis Disease 
Activity Index (range 0 ± 10) (9), and PsAQoL is the psoriatic arthritis quality of life measure 
(10). This formula was obtained by regression analysis using the GRACE data set (2) and 
explained 71% of the variance in sf36pcs scores (R2adj = 0.71). 
. 
The score range of the PASDAS is 0 ± 10, with worse disease activity represented by higher 
scores. 
Modified GRACE index 
The GRACE is a composite score comprising assessments of joints, skin, pain, function and 
health related quality of life. Each domain is transformed into a µGHVLUDELOLW\¶VFDOHand the 
items then combined arithmetically (4). The variables transformed are: 
x 68 tender joint count 
x 66 swollen joint count 
x Health assessment questionnaire (HAQ)  
x Patient global assessment of disease activity by VAS 
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x Patient VAS for skin 
x Patient VAS for joints 
x Psoriasis area and severity index (PASI) 
x Psoriatic arthritis quality of life index (PsAQoL) 
 
In the TICOPA study a VAS for skin was not collected and this item was thus omitted from 
the scale. Omitting the VAS for skin does not affect the score range as the score reflects the 
arithmetic mean of the individual components. 
The GRACE index has a score range of 0 ± 10 with worse disease activity represented by 
higher scores. 
Modified Composite psoriatic arthritis disease activity index (CPDAI).  
This index measures disease activity in 5 domains: peripheral joints, skin, enthesitis, 
dactylitis, and spine (3).  Within each domain severity was graded as 0 (none), 1 (mild), 2 
(moderate) and 3 (severe), according to pre-defined cut-offs (indicated in online 
supplementary table S1).  
In the TICOPA study the Ankylosing spondylitis Quality of Life index was not obtained so this 
was substituted by the PsAQoL (range 0 ± 20) using the same cut-off of 6. In addition the 
DLQI was estimated using the following equation: 
DLQI =0.533 + (1.98 * HAQ) + (0.165 * PSAQOL) + (0.405 * PASI). 
This formula was obtained by regression analysis using the GRACE data set (2) and 
explained 35% of the variance in DLQI scores (R2adj = 0.35). 
 
Statistical Analysis 
All statistical analyses were carried out in SPSS version 21. Where necessary, missing 
component data were replaced by carrying forward the last available observation. Comparison 
between groups at 48 weeks was made using an analysis of covariance with baseline values 
as the covariate. In addition, treatment groups were compared by calculating the area under 
the curve and comparing the area with independent t tests. We performed these analyses for 
all participants and, in addition, for those with oligoarthritis. Using previously defined cut-offs 
we examined the proportion of people in each arm of the trial achieving good, moderate or 
poor outcome for each composite measure at 48 weeks (4), comparing these proportions with 
the chi squared test.  
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Results 
The study population consisted of 206 patients randomly assigned to either the TC (n=101, 
49·0%) or SC (n=105, 51·0%). The baseline demographics of participants was, for TC and SC 
respectively, median age 46 years (range 18, 81) and 45 years (range 19, 71), males 53% 
and 52%, and median duration of disease 0.9 months (range 0, 21.4) and 0.7 months (range 
0, 23.6). In TC, 89·1% (n=90) of patients completed treatment and follow-up to week 48 with 
a similar proportion in SC (n=92, 87·6%).  
Baseline composite scores differed, with the tight control having higher baseline scores. Mean 
scores for each measure at each major timepoint are given, along with the statistical analysis, 
in Table 1. The baseline individual domain scores for each of the composite measures for the 
entire population are given in the online supplementary table S2. Analysis of covariance, 
adjusting for baseline data, for all available data demonstrated a highly significant difference 
for each of the composite measures. AUC analysis also showed significant differences 
between groups for PASDAS but not GRACE and CPDAI. The dynamics of change for each 
composite measure are illustrated in the Figure. For all measures there was separation 
between the groups DW WKH ILUVW µEOLQGHG¶ DVVHVVPHQW SRLQW ZLWK IXUWKHU GLYHUJHQFH DW
subsequent time points. For information, the CPDAI is reported by domain at baseline and 48 
weeks in the online supplementary table S3. 
 
The data for patients with oligoarthritis at study entry are given in Table 2. The baseline 
individual domain scores for the group with oligoarthritis are given in the online supplementary 
table S4. Although comparison of groups by analysis of covariance achieved significance, the 
statistics were smaller than those found for the entire cohort, and the mean values for each 
measure were reduced. Further, AUC analysis failed to show a difference between treatment 
arms for all of the measures tested but the number of participants for the analysis was small. 
Of note, the mean figures for each composite measure did not diverge until 24 weeks for this 
PsA subgroup. 
7KHSURSRUWLRQRISHRSOHDFKLHYLQJµJRRG¶ µPRGHUDWH¶DQGµSRRU¶UHVSRQVHDWZHHNVIRU
each measure, is given in Table 3. For the PASDAS 64.5% of people who achieved a µgood¶ 
response were in the TC arm, and 68.9% of those who achieved DµSRRU¶UHVSRQVH were in the 
SC arm. The figures for the GRACE index were 63.6% and 66.3% respectively, and for the 
CPDAI 66.7% and 63.7%. For each measure the difference in proportions was highly 
significant.  
7 
 
Dynamics of response in TICOPA 
 
 
Discussion 
The TICOPA study was the first  to show that a treat to target approach improved clinical 
outcomes for patients with early PsA.  The primary outcome was the composite measure 
developed for RA clinical trials, the ACR20. However, secondary outcomes demonstrated 
benefits across both articular and skin domains, although not for dactylitis and enthesitis. The 
current study describes the treatment response in terms of disease activity using three 
validated composite disease activity measures, all of which assess disease activity across 
several domains. Early separation was seen between the treatment groups with significant 
differences at 48 weeks and significantly more patients in the TC arm achieving a good clinical 
outcome. However, it must be acknowledged that these three composite measures were not 
assessed in their entirety in the TICOPA study, and that adaptations had to be made for the 
scores to be obtained. If the required data had been available it is possible that the measures 
would have behaved differently. 
The early separation between treatment groups at 12 weeks was probably due to the more 
aggressive use of methotrexate. As reported in the original paper, subjects in the TC arm had 
rapid escalation of oral methotrexate to 25mg weekly and this was reflected in the numbers 
achieving that dose at 3 months (TC 82.2%; SC 7.6%). If the minimal disease activity target 
had not been reached at 12 weeks sulfasalazine was added to methotrexate so that the 
continued and more pronounced separation of treatment groups between 12 and 24 weeks 
was partly attributable to this combination therapy. This is important as it would be 
advantageous to be able to predict who would respond to either methotrexate alone or 
combination conventional disease modifying therapy. Beyond 24 weeks TC patients who 
continued to have active disease were eligible for biologic therapy with TNF blockers and the 
further relative improvement seen in the TC arm beyond 24 months probably reflects this. 
In the subgroup of people with oligoarthritis contrasting results were obtained. The composite 
scores were lower at baseline, as would be expected, but the early difference seen for the 
entire cohort was not seen for the oligoarthritis sub-group alone. This result may reflect the 
possibility that none of the composite measures is appropriate for assessing disease activity 
where joint counts are low. An alternative explanation is that there is a a lack of effect of 
methotrexate in patients with oligoarthritis. In this respect it is worth noting that in the landmark 
methotrexate in psoriatic arthritis (MIPA) trial better results were seen in the polyarticular 
subset of the disease (11). More data is needed on the appropriate treatment strategy for this 
common subgroup of PsA. 
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At the time the TICOPA study was commenced validated composite measures for psoriatic 
arthritis were unavailable so that not all appropriate outcomes were measured to allow 
calculation of the PASDAS, CPDAI and GRACE. However, we were able to make an 
allowance for the missing measures, either by estimating, using available measures or, in 
the case of the GRACE instrument, a modular measure, to omit the outcome (a skin VAS 
score). The effect of these modifications on the performance of the measures is difficult to 
assess: an independent data set in which all these variables are collected would inform this 
question. The new composite measures assess disease activity in domains other than the 
joints, and offer more responsiveness, together with larger effect sizes, in clinical trials (12). 
In future it would be appropriate to use such measures as the primary outcome in clinical 
trials as it is likely that fewer patients will be needed to show a difference in treatment arms. 
The PASDAS is currently being used in this way (13).  
Which of the composite measures performs best in this study? In the overall patient population 
there is probably little to choose between them, although the statistics for the PASDAS exceed 
those for the GRACE and CPDAI. Similarly, the PASDAS outperforms the GRACE and CPDAI 
using area under the curve analysis. Similar contrasts are evident in the analysis of the 
oligoarthritis patients. Each of the measures differs in construction: the PASDAS uses a 
weighted formula, the GRACE a modular scheme ZLWKHDFKGRPDLQXVLQJDµGHVLUDELOLW\¶VFDOH, 
and the CPDAI also using a modular scheme in which patients are categorised within domain 
(2). Each of the measures covers a similar range of domains but the CPDAI is the only 
measure addressing the five major domains of joints, skin, enthesitis, dactylitis and spine. The 
relative performance of the measures may have been a function of the patients enrolled in the 
study - spinal involvement was not prominent, nor was the skin component ± and the 
measures may perform relatively differently in alternative patient populations. In terms of 
outcome all three measures gave a similar result (Table 3) but it is worth noting that the cut-
offs for outcome are still preliminary, although they have demonstrated good ability to 
distinguish radiographic progression in an alternative data set (14). 
In conclusion, the performance of several novel composite disease activity measures have 
been examined using data from the TICOPA trial. Each measure was able to distinguish 
between treatment arms, although all three showed diminished ability to distinguish treatment 
effect for patients with oligoarthritis. Further data are needed to guide the decision on selecting 
a preferred  composite measure for use as the primary outcome in PsA clinical trials. 
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Figure legend. Change in scores for each composite measure in each treatment arm in the 
TICOPA study.    
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Table 1. Comparison of composite measures with analysis of covariance and area under of curve for all patients. 
 ?& ?ĂŶĚ ?ƚ ?ĂƌĞƚĞƐƚƐƚĂƚŝƐƚŝĐƐ ? 
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n Tight control 
N = 101 
n Standard Care 
N = 105 
Analysis of covariance 
F                       p                         N 
Area under 
curve 
t               p 
PASDAS Baseline 88 5,36 ± 1.42 85 5.09 ± 1.33      
12 
weeks 
87 4.08 ± 1.37 85 4.44 ± 1.64 
     
24 
weeks 
88 3.60 ± 1.58 85 4.25 ± 1.88 
13.4 <0.0001    
36 
weeks 
88 3.34 ± 1.74 85 4.21 ± 1.73 
     
48 
weeks 
88 3.17 ± 1.64 85 4.02 ± 1.80 
18.0 < 0.0001 173 2.57 0.01 
GRACE Baseline 97 4.37 ± 1.68 96 4.06 ± 1.64      
12 
weeks 
96 3.27 ± 1.70 96 3.44 ± 1.78 
     
24 
weeks 
97 2.76 ± 1.77 96 3.21 ± 1.98 
7.5 0.007    
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36 
weeks 
97 2.55 ± 1.97 96 3.21 ± 2.03 
     
48 
weeks 
96 2.32 ± 1.96 96 2.98 ± 2.00 
14.5 < 0.0001 192 1.44 0.15 
CPDAI Baseline 89 7.83 ± 2.74 89 7.26 ± 2.62      
 12 
weeks 
89 5.88 ± 2.80 89 6.06 ± 2.81 
     
 24 
weeks 
88 5.21 ± 2.70 89 5.91 ± 3.13 
8.1 0.005    
 36 
weeks 
89 4.79 ± 2.82 89 5.56 ± 3.02 
     
 48 
weeks 
88 4.46 ± 2.63 89 5.60 ± 3.10 
15.9 < 0.0001 177 1.22 0.23 
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Table 2 Comparison of composite measures with analysis of covariance and area under of curve for patients with oligoarthritis at study entry. 
  ?& ?ĂŶĚ ?ƚ ?ĂƌĞƚĞƐƚƐƚĂƚŝƐƚŝĐƐ ? 
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n Tight control 
N = 27 
n Standard Care 
N = 30 
Analysis of covariance       
       F                               p             
N 
Area under 
curve 
     t                
p 
PASDAS Baseline 21 4.14 ± 1.10 23 4.15 ± 0.80      
12 weeks 20 3.30 ± 1.33 23 3.24 ± 1.04      
24 weeks 21 2.82 ± 1.35 23 3.49 ± 1.65 2.8 0.10    
36 weeks 21 2.97 ± 1.87 23 3.45 ± 1.49      
48 weeks 21 2.61 ± 1.50 23 3.48 ± 1.53 4.7 0.04 44 0.94 0.35 
GRACE Baseline 26 2.77 ± 1.06 28 2.74 ± 1.09 
 
    
12 weeks 25 2.23 ± 1.41 28 2.21 ± 1.10      
24 weeks 26 1.80 ± 1.42 28 2.24 ± 1.51 1.0 0.33    
36 weeks 26 1.76 ± 1.86 28 2.40 ± 1.75      
48 weeks 26 1.39 ± 1.49 28 2.29 ± 1.61 6.6 0.01 54 0.97 0.34 
CPDAI Baseline 22 5.86 ± 2.12 24 5.38 ± 2.22      
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Table 3 ?EƵŵďĞƌƐĂĐŚŝĞǀŝŶŐ ?ŐŽŽĚ ? ? ?ŵŽĚĞƌĂƚĞ ?ĂŶĚ ?ƉŽŽƌ ?ƌĞƐƉŽŶƐĞat 48 weeks according to each measure and according to treatment group  
 
 
 
 
 
 
 12 weeks 22 4.64 ± 2.11 24 4.58 ± 2.17      
 24 weeks 21 4.00 ± 1.76 24 4.54 ± 2.64 0.8 0.38    
 36 weeks 22 4.00 ± 2.76 24 4.46 ± 2.57      
 48 weeks 22 3.59 ± 2.24 24 4.46 ± 2.45 4.5 0.04 46 0.37 0.72 
 Tight control  Standard care  ɍ2 p 
  ?'ŽŽĚ ?
response 
 ?DŽĚĞƌĂƚĞ ? 
response 
 ?WŽŽƌ ?
response 
Total  ?'ŽŽĚ ?
response 
 ?DŽĚĞƌĂƚĞ ?
response 
 ?WŽŽƌ ?
response 
Total   
PASDAS N (%) 40 (46 29 (33) 19 (21) 88 (100) 22 (26) 21 (25) 42 (49) 85 (100) 15.1 0.001 
GRACE N (%) 35 (37) 32 (33) 29 (30) 96 (100) 20 (21) 19 (20) 57 (59) 96 (100) 16.5 0.0001 
CPDAI N (%) 34 (39) 15 (17) 39 (44) 88 (100) 17  (19) 9 (10) 63 (71) 89 (100) 14.0 0.001 
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